Skip to main
NUVL

Nuvalent (NUVL) Stock Forecast & Price Target

Nuvalent (NUVL) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nuvalent Inc., a clinical-stage biopharmaceutical company, is developing targeted therapies for oncogene-driven non-small cell lung cancer (NSCLC), with promising candidates NVL-520 and NVL-655 showing deep and durable antitumor responses along with improved tolerability. The addressable market for these therapies is projected to exceed $3.6 billion, driven by the anticipated expansion of the patient demographic due to enhanced ROS1 detection capabilities and best-in-class drug profiles that promise longer efficacy durations and better safety. The company's innovative approach positions it favorably against established competitors like Alecensa and Xalkori, suggesting significant growth potential and an opportunity to reshape the treatment landscape for NSCLC.

Bears say

Nuvalent Inc. faces significant near-term risks that could adversely affect its stock valuation, primarily concerning the clinical outcomes of its leading product candidates, NVL-520 and NVL-655. Poor clinical results may result in downward revisions to market penetration estimates, increased discount rates, and potentially extended timelines for regulatory approval, thereby limiting commercialization opportunities. Additionally, the emergence of competitive products, regulatory challenges, and potential safety concerns could further threaten the company's market positioning and financial outlook.

Nuvalent (NUVL) has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nuvalent and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nuvalent (NUVL) Forecast

Analysts have given Nuvalent (NUVL) a Buy based on their latest research and market trends.

According to 16 analysts, Nuvalent (NUVL) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nuvalent (NUVL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.